Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. OptiNose, Inc.
  6. Summary
    OPTN   US68404V1008

OPTINOSE, INC.

(OPTN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/23/2021 11/24/2021 11/26/2021 11/29/2021 11/30/2021 Date
1.66(c) 1.69(c) 1.61(c) 1.61(c) 1.59 Last
454 955 244 103 267 236 627 261 388 348 Volume
+7.10% +1.81% -4.73% 0.00% -1.24% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 74,2 M - -
Net income 2021 -84,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,05x
Yield 2021 -
Sales 2022 114 M - -
Net income 2022 -50,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,40x
Yield 2022 -
Capitalization 131 M 131 M -
Capi. / Sales 2021 1,76x
Capi. / Sales 2022 1,14x
Nbr of Employees 206
Free-Float 71,5%
More Financials
Company
OptiNose, Inc. is a specialty pharmaceutical company that is focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. The Company’s products candidates include XHANCE (fluticasone propionate) and ONZETRA Xsail. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 mcg, is therapeutic utilizing its proprietary... 
Sector
Pharmaceuticals
Calendar
03/10Earnings Release
More about the company
Ratings of OptiNose, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about OPTINOSE, INC.
11/23Optinose to Present at the Piper Sandler Virtual Healthcare Conference
AQ
11/18Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
11/18Optinose Announces Closing of $46.0 Million Public Offering of Common Stock
AQ
11/18OPTINOSE : Announces Proposed Public Offering of Common Stock - Form 8-K
PU
11/18OPTINOSE, INC. : Entry into a Material Definitive Agreement, Other Events, Financial State..
AQ
11/16OptiNose Prices $40 Million Share Offering; Shares Plummet
MT
11/16OPTINOSE, INC. : Entry into a Material Definitive Agreement, Termination of a Material Def..
AQ
11/16OPTINOSE, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/16Optinose Announces Pricing of Public Offering of Common Stock
AQ
11/15OPTINOSE : Q3 Earnings Snapshot
AQ
11/15OptiNose Plans Share Offering -- Stock Falls 16% After-Hours
MT
11/15Optinose Announces Proposed Public Offering of Common Stock
GL
11/15OPTINOSE : Reports Third Quarter 2021 Financial Results and Recent Operational Highlights ..
PU
11/15OPTINOSE, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
11/15Earnings Flash (OPTN) OPTINOSE Posts Q3 Revenue $21.8M, vs. Street Est of $23.5M
MT
More news
News in other languages on OPTINOSE, INC.
11/16OptiNose propose une offre d'actions de 40 millions de dollars ; les actions s'effondre..
11/15OptiNose propose une offre d'actions - le titre chute de 16 % après les heures de négoc..
11/15Earnings Flash (OPTN) OPTINOSE affiche un chiffre d'affaires de 21,8 millions de dollar..
11/15Optinose, Inc. fournit des prévisions de résultats pour l'ensemble de l'année 2021
More news
Analyst Recommendations on OPTINOSE, INC.
More recommendations
Chart OPTINOSE, INC.
Duration : Period :
OptiNose, Inc. Technical Analysis Chart | OPTN | US68404V1008 | MarketScreener
Technical analysis trends OPTINOSE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 1,59 $
Average target price 9,20 $
Spread / Average Target 479%
EPS Revisions
Managers and Directors
Peter Kaighn Miller Chief Executive Officer & Director
Ramy A. Mahmoud President & Chief Operating Officer
Keith Alan Goldan Chief Financial Officer
Joseph C. Scodari Independent Chairman
John C. Messina SVP-Clinical Development & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
OPTINOSE, INC.-61.59%132
JOHNSON & JOHNSON1.16%420 557
ROCHE HOLDING AG15.70%334 662
PFIZER, INC.42.35%294 114
NOVO NORDISK A/S67.75%247 392
ELI LILLY AND COMPANY50.93%231 027